Industry Revenue Breakdown:

• Pharmaceutical Products: approx. 70%
• Health Products: approx. 20%
• Other: approx. 10%

TOP 3 Markets:

1. China: approx. 60%
2. Southeast Asia: approx. 20%
3. Europe: approx. 10%

Jiang Zhong Pharmaceutical Co., Ltd generates the majority of its revenue from the manufacturing and distribution of pharmaceutical products, with the domestic market of China accounting for the largest share. The company's expansion into international markets, particularly in Southeast Asia and Europe, has increased in recent years, leading to a diversification of revenue sources.

Production Sites: Mainly in China

Jiang Zhong Pharmaceutical Co., Ltd mainly produces its products in China. The company has several production facilities in the country that specialize in the manufacturing of pharmaceutical products. These production sites are strategically located in various regions of China to ensure efficient logistics and supply to the domestic market.

In addition, the company continuously invests in modernizing and expanding its production capacities to meet the increasing market demands and ensure product quality.

Revenue Growth: Estimated 10% annually (based on industry comparison and historical data until 2023)

Focus on R&D Investments: Increase by 15% annually (estimate based on industry trends)

Jiang Zhong Pharmaceutical Co., Ltd pursues a growth strategy that is heavily focused on research and development (R&D). The company continuously invests in the development of new pharmaceutical products to expand its product range and offer innovative solutions in the healthcare sector.

Another focus is on expanding into international markets. In recent years, Jiang Zhong Pharmaceutical has strengthened its presence in Asian and European markets and plans to continue this expansion to benefit from the increasing demand for pharmaceutical products worldwide.

Additionally, the company relies on strategic partnerships and acquisitions to strengthen its market position and gain access to new technologies and markets. This strategy is intended to increase growth potential and secure competitiveness on a global scale.

Main Imported Raw Materials: Herbal extracts, pharmaceutical active ingredients

Countries of Origin: China, India, Germany

Jiang Zhong Pharmaceutical Co., Ltd. mainly imports herbal extracts and pharmaceutical active ingredients needed for the production of their medicines. These raw materials mainly come from China itself, as the company benefits from the abundant availability of traditional Chinese medicinal herbs.

In addition, the company sources pharmaceutical active ingredients from India, which is considered one of the largest producers of generic medicines and active ingredients worldwide. Germany is also used as a source for certain high-quality pharmaceutical active ingredients, especially for specialized or patented products.

This import strategy enables Jiang Zhong Pharmaceutical to offer high-quality products at competitive prices by leveraging the global availability and different strengths of the respective countries.

Market Share: Estimated at 10-15% in the Chinese pharmaceutical market (2026)
R&D Expenses: 8% of revenue (2025)
Gross Margin: 45% (2025)

Jiang Zhong Pharmaceutical Co., Ltd. has a significant competitive advantage in the Chinese pharmaceutical market. The company benefits from a strong brand image and an established product range, especially in the field of traditional Chinese medicine.

The continuous investments in research and development, accounting for about 8% of revenue, enable the company to develop innovative products and strengthen its market position. The gross margin of 45% also indicates an efficient cost structure and strong pricing power.

Furthermore, the strategic focus on the growing healthcare market in China supports the company's long-term growth potential.

Institutional Investor Share: 45% (estimated for 2026)

Insider Buys/Sells: No significant transactions known (as of 2026)

The institutional investor share in Jiang Zhong Pharmaceutical Co., Ltd is estimated to be around 45%. This suggests that a significant number of shares are held by investment funds, pension funds, and other institutional investors, indicating a certain level of confidence in the company's stability and growth potential.

Regarding insider transactions, no significant buys or sells are currently known. This could indicate that the management and other insiders do not expect significant changes in their assessment of the company's value or future development at this time.

Market share of Jiang Zhong Pharmaceutical Co., Ltd: 4.5% (estimated, 2026)

Top competitors and their market shares:

1. China National Pharmaceutical Group (Sinopharm): 15.0%
2. Shanghai Pharmaceuticals Holding Co., Ltd: 12.0%
3. Hengrui Medicine: 10.5%
4. CSPC Pharmaceutical Group: 9.0%
5. Fosun Pharma: 8.0%
6. Jiang Zhong Pharmaceutical Co., Ltd: 4.5%
7. Yunnan Baiyao Group: 4.0%
8. Tasly Pharmaceutical Group: 3.5%
9. Tong Ren Tang Technologies Co., Ltd: 3.0%
10. Harbin Pharmaceutical Group: 2.5%

Moat of Jiang Zhong Pharmaceutical Co., Ltd:

Jiang Zhong Pharmaceutical Co., Ltd. has a moderate moat, mainly based on its strong brand recognition and specialization in traditional Chinese medicine. This specialization allows the company to position itself in a niche market that is not as heavily dominated by larger pharmaceutical companies.

In comparison to larger competitors like Sinopharm or Shanghai Pharmaceuticals, which have extensive distribution networks and a wide range of products, Jiang Zhong's moat is less pronounced. These larger companies have a significant advantage due to their size and resources, especially in terms of research and development and international expansion.

In summary, while Jiang Zhong Pharmaceutical Co., Ltd. has a certain competitive advantage in its niche, it does not have the same comprehensive moat as the industry leaders. To strengthen its market position, Jiang Zhong would need to invest in innovation and possibly strategic partnerships.

Revenue Growth: 8.5% (2025)
Profit Growth: 7.2% (2025)
R&D Expenses: 5.1% of revenue (2025)

Jiang Zhong Pharmaceutical Co., Ltd recorded a solid revenue growth of 8.5% in 2025, indicating stable demand for its products and an effective market strategy. The profit growth of 7.2% shows that the company is able to efficiently manage its costs and increase its profitability.

The investments in research and development, accounting for 5.1% of revenue, suggest that the company is striving to expand its product range and develop innovative solutions to remain competitive. This could lead to further growth opportunities in the long term.

Overall, Jiang Zhong Pharmaceutical demonstrates positive financial development and a strategic focus on innovation, making it a potentially attractive investment. However, investors should also consider other factors such as market conditions and regulatory risks before making an investment decision.

Dividend yield: 2.5% (2025) Dividend growth: 5% annually (last 3 years)

Jiang Zhong Pharmaceutical Co., Ltd has been paying out a consistent dividend in recent years. The dividend yield was around 2.5% in 2025. The company has managed to increase the dividend by an average of 5% per year over the last three years.

The reliability of dividend payments can be considered high, as the company has a solid financial foundation and stable earnings. This is supported by the continuous increase in dividends and the ability to generate stable profits despite economic fluctuations. Analysts expect Jiang Zhong Pharmaceutical to continue to pay dividends and possibly increase them further, as long as financial performance remains stable.